Navigation Links
InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008
Date:11/5/2008

(0.02) N/A

Adj. EBITDA EPS - diluted 0.19 (0.02) N/A

Reconciliation from Net Income to Adjusted EBITDA:

(in thousands, except per share data)

Nine Months Ended September 30

I-Flow Predecessor

2008 2007 2007

Net Income $8,700 $(928) $3,604

Adjustments:

Interest expense 2,828 33 (237)

Interest income (14) (3,534) -

Income tax expense 399 752 2,460

Depreciation -- Pumps 2,908 - 2,307

Depreciation -- Other 133 - 125

Amortization 1,370 - -

EBITDA $16,325 $(3,677) $8,259

Adjustments:

(Gain) loss on derivatives (8,665) 675 -

Stock based compensation 1,166 1,490 305

Adj. EBITDA $8,826 $(1,512) $8,564

Adj. EBITDA EPS - basic 0.50 (0.08) N/A

Adj. EBITDA EPS - diluted 0.47 (0.08) N/A

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the grow
'/>"/>

SOURCE InfuSystem Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
2. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
3. BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service
4. China Pharma Holdings, Inc. Appoints The Ruth Group
5. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
6. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
7. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
8. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
9. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
10. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
11. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... fossilized tracksite in southern Africa shows how early dinosaurs ... slippery and sloping terrain. Differences in how early dinosaurs ... of the group. The research, conducted by researchers ... Aires, and the Iziko South African Museum in Cape ...
... risk of allergy. Cathleen Muche-Borowski and her coauthors present ... current issue of Deutsches rzteblatt International (Dtsch ... becoming increasingly common in Western industrialized countries. As there ... hay fever, or atopic eczema, the prevention of these ...
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
Cached Biology News:Trackway analysis shows how dinosaurs coped with slippery slopes 2Trackway analysis shows how dinosaurs coped with slippery slopes 3NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3